Study	Reason for exclusion
Andreu 1993	Outcomes: measured human leukocyte antigen alloimmunisation, not clinical effectiveness
AuBuchon 2005	Participants: healthy people
Ayupova 2014	Non‐RCT: a retrospective cohort study included 33 people with malignant chronic lymphocytic leukaemia
Berger 2013	Non‐RCT: economic model calculations were structured to estimate the clinical and safety benefits of pathogen inactivation
Blundell 1996	Intervention: platelets were treated with ultraviolet B irradiation only. Ultraviolet B irradiation is used to prevent the formation of antiplatelet alloantibodies and refractoriness to platelet transfusions, not to reduce or remove pathogens.
Cid 2012	Review
Cook 2013	A review of 6 RCTs of pathogen‐inactivated platelets
Corash 2000	Participants: healthy people
Corash 2012	Case studies reporting on respiratory adverse events after transfusion of Intercept platelet components
Drawz 2015	Prospective cohort study
Dumont 2010	Participants: healthy people
Infanti 2011	Cohort study conducted on people requiring platelet support because of thrombocytopenia
MacLennan 2015	Intervention: cross‐over RCT involving thrombocytopenic haematology patients receiving 2‐ to 5‐ versus 6‐ or 7‐day‐stored platelets
NCT00742001	Non‐RCT: phase I study involving healthy participants to evaluate the recovery and survival of red blood cells retrieved from Mirasol‐treated whole blood
NCT01615146	RCT comparing therapeutic standard platelet transfusion with prophylactic standard platelet transfusion
NCT02330081	Non‐RCT: prospective, intra‐subject controlled, open‐label design Platelets were treated with Mirasol pathogen reduction technology; the recovery and survival of the platelets were measured in vitro.
NCT02653443	RCT comparing apheresis platelets prepared with the Intercept Blood System for Platelets versus apheresis conventional untreated platelets in healthy participants
Rummler 2013	Retrospective cohort study on pathogen‐reduced plasma in plasma therapy.
Sigle 2013	Non‐RCT: observational study involving haematologic participants assigned to receive platelets treated with amotosalen‐based pathogen reduction technology or conventional platelets.
TRAP 1997	Intervention: platelets were treated with ultraviolet B irradiation only. Ultraviolet B irradiation is used to prevent the formation of antiplatelet alloantibodies and refractoriness to platelet transfusions, not to reduce or remove pathogens.
Vamvakas 2012	Review including 5 RCTs evaluating the amotosalen‐hydrochloride/ultraviolet A light technology. Cross‐over studies were excluded.

RCT: randomised controlled trial